Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Inmune Bio, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 37 | 48 | +11 |
| Shares | 2.14M | 2.29M | +158.5K (+7.4%) |
| Value | $14.5M | $25.8M | +$11.3M (+78.2%) |
New holders (14)
Institutions that held Inmune Bio, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 43,134 | $485.7K | 0.00% |
| Citigroup Inc | 35,900 | $404.2K | 0.00% |
| Laird Norton Trust Company, LLC | 31,500 | $354.7K | 0.04% |
| Qube Research & Technologies Ltd | 29,437 | $331.5K | 0.00% |
| Millennium Management LLC | 24,204 | $272.5K | 0.00% |
| Balyasny Asset Management LLC | 23,258 | $261.9K | 0.00% |
| 683 Capital Management, LLC | 19,253 | $216.8K | 0.02% |
| Rockefeller Capital Management L.P. | 18,220 | $205.2K | 0.00% |
| Man Group plc | 15,654 | $176.3K | 0.00% |
| ExodusPoint Capital Management, LP | 14,948 | $168.0K | 0.00% |
| Financial Advocates Investment Management | 12,500 | $140.8K | 0.01% |
| Laurion Capital Management LP | 11,011 | $124.0K | 0.00% |
| JPMorgan Chase & Co | 3,479 | $39.2K | 0.00% |
| FNY Investment Advisers, LLC | 100 | $1.00K | 0.00% |
Sold out (3)
Institutions that held Inmune Bio, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Squarepoint Ops LLC | 10,308 | $70.5K |
| Northwestern Mutual Wealth Management Co | 4,300 | $29.1K |
| Asset Dedication, LLC | 814 | $6.00K |